OptiNose, Inc.

OPTN

US68404V1008

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 29/05/2024 am IST			5-day change	1st Jan Change
1.17 ^USD	+5.41%		+0.86%	-9.30%

14/05	Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024
14/05	Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M	MT

Optinose Provides Revenue Guidance for the Full Year of 2021

May 05, 2021 at 02:30 pm IST

Optinose provided revenue guidance for the full year of 2021. The company expects XHANCE net revenues for the full year of 2021 to be at least $80 million. In addition, the Company expects full year 2021 XHANCE net revenue per prescription to increase compared to full year 2020 XHANCE net revenue per prescription of $185.

Latest news about OptiNose, Inc.

Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024	14/05
Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M	14/05	MT
OptiNose, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024	09/05	CI
OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024	25/04	CI
Transcript : OptiNose, Inc. - Special Call	25/04
OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025	25/04	CI
Optinose, Inc. Announces Preliminary XHANCE Net Product Revenue Results for the First Quarter Ended March 31, 2024	25/04	CI
Lake Street Adjusts Price Target on OptiNose to $4 From $3, Maintains Buy Rating	18/03	MT
Sector Update: Health Care Stocks Steady Premarket Monday	18/03	MT
OptiNose Says US FDA Approves Xhance to Treat Chronic Rhinosinusitis	16/03	MT
Optinose Says FDA Approves Xhance to Treat Chronic Rhinosinusitis	16/03	DJ
OptiNose, Inc. Announces U.S. Food and Drug Administration Approved XHANCE (Fluticasone Propionate) Nasal Spray for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps in Patients 18 Years of Age and Older	16/03	CI
Optinose, Inc. Provides Update on Hikma Manufacturing Agreement	15/03	CI
HC Wainwright Initiates OptiNose With Buy Rating, $5 Price Target	11/03	MT
Transcript : OptiNose, Inc., Q4 2023 Earnings Call, Mar 07, 2024	07/03
Earnings Flash (OPTN) OPTINOSE Posts Q4 Revenue $19.9M	07/03	MT
OptiNose, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03	CI
OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024	07/03	CI
OptiNose, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03	CI
North American Morning Briefing : Powell Still in -2-	07/03	DJ
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology	18/01	CI
OptiNose, Inc.(NasdaqGS:OPTN) dropped from NASDAQ Biotechnology Index	15/12	CI
Optinose Shares Slide Premarket as FDA Extends Xhance Review	06/12	DJ
OptiNose Says US FDA Extended Review of Supplemental New Drug Application for Xhance in Chronic Rhinosinusitis	06/12	MT

Chart OptiNose, Inc.

Duration

Period

More charts

Company Profile

OptiNose, Inc. is a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing its Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE combines the EDS with a liquid formulation of fluticasone propionate, a well-characterized, second-generation corticosteroid. XHANCE is designed to deliver medication into the high and deep regions of the nasal passages where both nasal polyps and inflamed and swollen membranes can obstruct normal sinus ventilation and drainage. The Company has developed both a liquid delivery EDS and a powder delivery EDS utilizing natural functional behaviors of the upper nasal airways intended to offer better drug deposition.

Sector

Pharmaceuticals

Calendar

06/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for OptiNose, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.17 USD

Average target price

3.75 USD

Spread / Average Target

+220.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
OPTINOSE, INC.	-9.30%	17Cr
ELI LILLY AND COMPANY	+38.59%	73TCr
JOHNSON & JOHNSON	-7.89%	35TCr
MERCK & CO., INC.	+15.66%	32TCr
ABBVIE INC.	+0.24%	27TCr
ASTRAZENECA PLC	+13.21%	24TCr
NOVARTIS AG	+7.22%	20TCr
ROCHE HOLDING AG	-6.18%	20TCr
AMGEN INC.	+4.23%	16TCr
PFIZER, INC.	-1.70%	16TCr

Other Pharmaceuticals

OptiNose, Inc.

Equities

OPTN

US68404V1008

Pharmaceuticals

Optinose Provides Revenue Guidance for the Full Year of 2021

EPS Revisions